SCHEMBL21389123

SCHEMBL21389123

CC1(C)CCC(=O)N(CCNC(=O)CSCC(=O)O)C1=O

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.36
▸ FABP3 P05413 1/20 0.36
▸ FABP4 P15090 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ MAPK1 P28482 1/20 0.32
▸ MTNR1A P48039 1/20 0.32
▸ MTNR1B P49286 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24796396 0.90 SMN1; SMN2 (0.33) L3MBTL1ALDH1A1KMT2AHPGDHTT
SCHEMBL21389277 0.87 GAA (0.38) GAAFABP3FABP4L3MBTL1ALDH1A1
SCHEMBL24796394 0.84 HPGD (0.41) GAAL3MBTL1ALDH1A1KMT2AHPGD
SCHEMBL21389103 0.84 KMT2A (0.44) GAAFABP3FABP4L3MBTL1ALDH1A1
SCHEMBL21389091 0.81 KMT2A (0.40) GAAFABP3FABP4L3MBTL1ALDH1A1
SCHEMBL24796381 0.81 GAA (0.35) GAAFABP3FABP4L3MBTL1ALDH1A1
SCHEMBL21389194 0.81 GAA (0.36) GAAFABP3FABP4L3MBTL1ALDH1A1
SCHEMBL21389253 0.80 GAA (0.34) GAAFABP3FABP4L3MBTL1ALDH1A1
SCHEMBL21389133 0.80 FABP4 (0.39) GAAFABP3FABP4L3MBTL1ALDH1A1
SCHEMBL24796116 0.79 FABP3 (0.37) GAAFABP3FABP4L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 — — US disclosed
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 — — US disclosed
US-11535660-B1 Modulators of G-protein coupled receptors Cannot Therapeutics, Inc. (US) 2022-12-27 — — US disclosed
WO-2019183577-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. (US) 2019-09-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR GAA 1526/4885FABP3 666/4885FABP4 1047/4885
US-11535660-B1 Modulators of G-protein coupled receptors GIPR, GLP1R, GCGR GAA 1536/4885FABP3 669/4885FABP4 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback